BioHarvest Announces Completion of Stage 1 Development for CDMO Contract with Nasdaq-Listed Pharmaceutical Company
Rehovot, Israel--(Newsfile Corp. - May 12, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced that the Company's previously announced CDMO contract with a Nasdaq-listed pharmaceutical company has progressed from Stage 1 to Stage 2...
Biotechnology, Pharmaceuticals, Health
2025-05-12 8:30 AM EDT | BioHarvest Sciences Inc.
BioMark Diagnostics Announces Landmark Publication Validating High Specificity and Accuracy of Its Early-Stage Lung Cancer Test
Vancouver, British Columbia--(Newsfile Corp. - May 12, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark"), a leading developer of liquid biopsy tests for early cancer detection, today announced the publication of a pivotal study as part of the special issue Molecular Pathogenesis and Diagnostics of Lung...
Technology, Biotechnology, Healthcare and Hospitals
2025-05-12 8:30 AM EDT | BioMark Diagnostics, Inc.
Dr. Christina Rahm's Merci Dupre Clothiers Presents Revolutionary Eco-Fashion Show Tonight in Spartanburg, SC
Spartanburg, South Carolina--(Newsfile Corp. - May 9, 2025) - Dr. Christina Rahm, renowned scientist, humanitarian, and founder of Merci Dupre Clothiers, will showcase her innovative sustainable fashion line tonight at a private hangar at Spartanburg Downtown Memorial Airport. The exclusive runway event will feature Merci Dupre's revolutionary eco-technology garments while...
Biotechnology, Food / Beverages, Health
2025-05-09 2:49 PM EDT | DRC Ventures
Neural Therapeutics Announces SERFOR Permit Renewal Submission and Extension of LOI with HANF.COM
Toronto, Ontario--(Newsfile Corp. - May 9, 2025) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company"), an ethnobotanical drug discovery company focused on developing therapeutic drugs for mental illnesses related to substance use disorders, is pleased to announce that it has submitted a renewal application to...
Biotechnology, Pharmaceuticals, Health, Psychedelics
2025-05-09 8:26 AM EDT | Neural Therapeutics Inc.
Kiora Pharmaceuticals Reports First Quarter Results; Initiating Two Phase 2 Trials for Treatment of Retinal Diseases; Cash and Short-term Investments Expected to Fund Operations into Late 2027
Encinitas, California--(Newsfile Corp. - May 9, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced first quarter 2025 financial results and provided an update on its pipeline of therapeutics for the treatment of retinal diseases. Key first quarter and 2025 year-to-date corporate highlights include:Received approval to...
Biotechnology, Pharmaceuticals
2025-05-09 7:00 AM EDT | Kiora Pharmaceuticals, Inc.
Hemostemix at Invest Stuttgart
Calgary, Alberta--(Newsfile Corp. - May 8, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is poised to make a significant impact at Invest Stuttgart 2025, Germany's premier finance and investment conference, taking place from May 9-10, 2025 at Messe Stuttgart. The event attracts thousands...
Biotechnology, Pharmaceuticals, Health
2025-05-08 9:12 AM EDT | Hemostemix Inc.
BioMark Diagnostics Announces Uplisting to OTCQB Venture Market
Vancouver, British Columbia--(Newsfile Corp. - May 8, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (OTCQB: BMKDF) (FSE: 20B) ("BioMark" or the "Company"), a leading developer of liquid biopsy tests for early cancer detection, is pleased to announce that its common shares have been officially approved for uplisting from the OTC...
Technology, Biotechnology, Healthcare and Hospitals
2025-05-08 8:30 AM EDT | BioMark Diagnostics, Inc.
Optimi Health Completes Largest-to-Date MDMA Export to Australia for PTSD Therapy
Vancouver, British Columbia--(Newsfile Corp. - May 8, 2025) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Canadian drug manufacturer and formulator of GMP-grade MDMA and natural psilocybin, has completed its largest international export to date of MDMA capsules to Australia, supporting the treatment...
Biotechnology, Pharmaceuticals, Health, Psychedelics
2025-05-08 7:00 AM EDT | Optimi Health Corp.
Therma Bright Inc. Provides Update on InStatin Development, Announcement of Key Strategic Advisor and Highlights Preclinical and IP Progress at InStatin
Toronto, Ontario--(Newsfile Corp. - May 8, 2025) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX) ("Therma" or the "Company"), a developer and investment partner specializing in advanced diagnostic and medical device technologies, is pleased to provide an update on the significant progress achieved at InStatin over the past...
Technology, Biotechnology, Health
2025-05-08 6:30 AM EDT | Therma Bright Inc.
Adaptimmune to Report Q1 2025 Financial and Business Updates on Tuesday, May 13, 2025
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - May 7, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, will report financial results and provide business updates for the first quarter of 2025, before the US markets open on Tuesday,...
Biotechnology, Healthcare and Hospitals
2025-05-07 12:00 PM EDT | Adaptimmune Therapeutics PLC
BioVaxys and Sona Nanotech Enter Research Collaboration
Vancouver, British Columbia, and Halifax, Nova Scotia--(Newsfile Corp. - May 7, 2025) - BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB) (OTCQB: BVAXF) ("BioVaxys") and Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) ("Sona") announce today that they have entered into a Research Agreement ("Agreement") to collaborate on the development of...
2025-05-07 9:12 AM EDT | Sona Nanotech Inc.
Phio Pharmaceuticals Announces Positive Pathology Results in Third Cohort in INTASYL PH-762 Skin Cancer Clinical Trial
Complete Pathologic Response reported in 2 patients in the Third Cohort with cutaneous squamous cell carcinoma, complementing results in prior cohort Phio to present trial results to date at a podium presentation at Society for Investigative Dermatology (SID) Annual Meeting on May 10thMarlborough, Massachusetts--(Newsfile Corp. - May 7, 2025) -...
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-05-07 7:45 AM EDT | Phio Pharmaceuticals Corp.
NervGen Pharma Announces Results of Annual General Meeting of Shareholders
All resolutions submitted for approval were passed by shareholdersVancouver, British Columbia--(Newsfile Corp. - May 7, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neurorestorative therapeutics, announces the results of its Annual General Meeting of Shareholders ("AGM") held on May 6, 2025.The company...
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-05-07 7:30 AM EDT | NervGen Pharma Corp.
IR-MED Awarded $500,000 Grant from the Israel Innovation Authority to Advance AI-Powered DiaSafe(TM) Device for Diabetic Foot Ulcer Assessment
DiaSafe™, IR-MED's second product, is being developed to provide safe, real-time optical readings of biomarkers for assessment of diabetic foot ulcers The most common cause of amputation, diabetic foot ulcers can be prevented with early assessment, improving patient care and healthcare economics in a
Technology, Biotechnology, Healthcare and Hospitals, Health
2025-05-05 8:30 AM EDT | IR-MED, Inc.
Optimi Health Obtains U.S. FDA Drug Establishment Registration
Vancouver, British Columbia--(Newsfile Corp. - May 5, 2025) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a manufacturer of GMP-certified MDMA and psilocybin, has received its U.S. FDA Establishment Identifier (FEI) number—a key regulatory step for engaging in FDA filings and compliant supply into...
Biotechnology, Pharmaceuticals, Health, Psychedelics
2025-05-05 7:35 AM EDT | Optimi Health Corp.
Kiora Pharmaceuticals Presents In Vivo Preclinical Data at ARVO 2025 Demonstrating the Potential of KIO-104 to Treat Proliferative Vitreoretinopathy
Encinitas, California--(Newsfile Corp. - May 5, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") today announced the results from a preclinical study demonstrating KIO-104 significantly reduced scar formation in an established in vivo model of proliferative vitreoretinopathy (PVR). The findings further support KIO-104 as a promising therapeutic...
Biotechnology, Pharmaceuticals
2025-05-05 7:00 AM EDT | Kiora Pharmaceuticals, Inc.
Theralase Clinical Data Presented at Canadian Bladder Cancer Forum and American Urological Association
Toronto, Ontario--(Newsfile Corp. - May 5, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of small molecules and their formulations, able to be activated by light, radiation, sound and/or other drugs, intended for the...
Technology, Biotechnology, Healthcare and Hospitals, Pharmaceuticals
2025-05-05 7:00 AM EDT | Theralase Technologies Inc.
Orpyx Medical Technologies Inc. to Present at the 2025 Bloom Burton & Co. Healthcare Investor Conference
Calgary, Alberta--(Newsfile Corp. - May 2, 2025) - Orpyx® Medical Technologies Inc. ("Orpyx"), a leader in digital health solutions for the prevention of diabetic foot complications, today announced that Justine Jones, Senior Vice President, Commercial, will present at the 2025 Bloom Burton & Co. Healthcare Investor Conference held at the...
Technology, Biotechnology, Investment Banking, Health
2025-05-02 10:08 AM EDT | Bloom Burton & Co. Inc.
Marvel Biosciences Announces Closing of Second Tranche of Private Placement
Calgary, Alberta--(Newsfile Corp. - May 2, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to announce that, further to its press release of March 28, 2025 and subject to approval of the TSX Venture Exchange (the...
2025-05-02 7:00 AM EDT | Marvel Biosciences Corp.
Envoy Medical Reports on First Quarter 2025 Results
White Bear Lake, Minnesota--(Newsfile Corp. - May 1, 2025) - Envoy Medical®, Inc. (NASDAQ: COCH) ("Envoy Medical"), a revolutionary hearing health company focused on fully implanted hearing devices, today announced its corporate and financial results for the first quarter ended March 31, 2025, as well as other subsequent events.Financial and...
Biotechnology, Healthcare and Hospitals
2025-05-01 4:30 PM EDT | Envoy Medical, Inc.